Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Microbiology Spectrum|November 25, 2025
Development of an RT-qPCR and a Next-Generation Sequencing approach to assess viral shedding of NDV-based SARS-CoV-2 variant vaccinesMarta Boza, Adam Abdeljawad, Stefan Slamanig, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responsesHsin-Ping Chiu, Yao Yu Yeo, Tsoi Ying Lai, et al.
The Journal of General Virology|March 25, 2026
SARS-CoV-2 Nsp15 facilitates immune evasion and viral replication by limiting multiple host innate immune pathways, including cGAS-STINGHsin-Ping Chiu, Yao Yu Yeo, Tsoi Ying Lai, et al.
Vaccines|February 26, 2026
AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in MiceJosé Luis Martínez-Guevara, Tsoi Ying Lai, Mitali Mishra, et al.
Vaccine|December 12, 2024
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challengeStefan Slamanig, Nicholas Lemus, Tsoi Ying Lai, et al.
Vaccine|April 16, 2024
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sexJose L Martínez, Nicholas Lemus, Tsoi Ying Lai, et al.
NPJ Vaccines|November 17, 2024
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approachIrene González-Domínguez, Eduard Puente-Massaguer, Adam Abdeljawad, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2026
Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccinesMitali Mishra, Eduard Puente-Massaguer, Andrew T Jones, et al.
The Journal of Infectious Diseases|January 3, 2025
A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of ConcernVictoria Dolange, Stefan Slamanig, Adam Abdeljawad, et al.
Molecular Therapy. Nucleic Acids|April 24, 2026
Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in miceIrene González-Domínguez, Marta Boza, Adam Abdeljawad, et al.
Pageof 2